Sermorelin

Growth hormone release is run by two signals from the hypothalamus. GHRH steps on the gas. Somatostatin steps on the brake. Ghrelin, from the stomach, adds a third input. The pituitary releases growth hormone in pulses, largest in deep sleep, and growth hormone prompts the liver and other tissues to make IGF-1, the growth factor that carries much of growth hormone’s effect.

Sermorelin is a copy of the gas pedal. Given intravenously or under the skin, it specifically stimulates growth hormone secretion from the anterior pituitary. It does not replace growth hormone. It asks the pituitary to release what it has made, so the amount is limited by the pituitary’s stores and by somatostatin’s brake.

That is the core of the argument for GHRH-based drugs. Reviews of growth hormone secretagogues describe release that stays pulsatile and subject to negative feedback, which can prevent the very high levels that injected growth hormone can produce. The trade-off is that sermorelin needs a pituitary that can still respond, and a short half-life means each push is brief.²⁴

Sermorelin’s first job was diagnostic. A single intravenous dose works like a knock on the pituitary’s door. If growth hormone rises quickly, the gland can make and release it. A 1999 review in BioDrugs described this as a rapid and relatively specific test for growth hormone deficiency.

It also produced fewer false alarms than older tests. Fewer children without growth hormone deficiency were wrongly flagged after sermorelin than after other provocative tests, which matters when the result decides whether a child starts years of injections. In adults, combining sermorelin with the amino acid arginine was more specific still.

The test has one blind spot that teaches something about the whole system. Sermorelin goes straight to the pituitary and skips the hypothalamus. A child whose problem lies in the hypothalamus, upstream of the pituitary, can respond normally to sermorelin and still be deficient. That is why the review advised confirming the diagnosis with other tests.²

Sermorelin’s longest-running human data, limited as they are, come from prepubertal children with idiopathic growth hormone deficiency. In the studies reviewed in 1999, injections under the skin significantly increased height velocity in some children, and the gains held through 12 months. Data from a few children suggested the effect lasted for 36 months of continued use.

Most of the children had catch-up growth. Those who responded best tended to be slow-growing, shorter children whose bone age and height age lagged behind their calendar age. The review does not say why. One possible reading is that these children had a pituitary that could still answer a push.

It did not clearly match the standard. In studies using other sermorelin schedules, gains in height velocity were smaller than in children receiving daily somatropin, recombinant growth hormone, and the recommended regimen was never compared directly. Its effect on final adult height had not been determined when the review was written.²

Growth hormone and IGF-1 fall steadily with age, and it would be easy to assume the pituitary simply wears out. A 1992 study at the National Institute on Aging tested that idea directly, and the result is worth knowing.

Researchers compared 9 healthy young men, average age 26, with 10 healthy older men, average age 68. At baseline the older men had lower IGF-1 and shorter bursts of growth hormone. Yet when both groups received an intravenous GHRH test, the older pituitaries released as much growth hormone as the young ones. The gland was still capable. One reading is that it was getting less of a push, though the study did not measure that directly.

Then the older men took GHRH(1-29), the sermorelin sequence, by injection in two 14-day courses at two doses, with 14 days off in between. At the higher dose, their 24-hour growth hormone, pulse size and IGF-1 rose to levels not statistically different from the young men’s. Fasting glucose, blood pressure and routine blood tests did not change.

This suggests that the signals reaching the pituitary change with age while the gland keeps much of its capacity, at least in healthy, lean older men. It is a small, short study, and restoring a hormone level is a different thing from improving health. Still, it explains why researchers kept testing GHRH in older adults.³

Two 1997 studies took the next step and looked for real-world changes. At Johns Hopkins, 11 healthy men aged 64 to 76 with low IGF-1 used GHRH(1-29) at home for six weeks. Nighttime growth hormone rose, yet IGF-1 did not. Two of six strength measures and one endurance test improved, while weight, body composition, glucose and lipids did not change.

The Hopkins authors suggested that how the peptide is given may matter. Their single nightly injection appeared less effective at producing growth hormone and IGF-1 effects than earlier approaches, which fits the short life of the peptide, though the study did not compare schedules directly.

A University of California study ran longer. Ten women and nine men aged 55 to 71 used a close analog of sermorelin for 16 weeks, after 4 weeks of placebo. IGF-1 rose within two weeks and drifted back toward baseline by the end. Skin thickness increased in both sexes. Lean mass, insulin sensitivity, well-being and libido improved in men only, and sleep quality did not change in either.

Read together, these trials show a real but modest and uneven signal. Hormones moved reliably, body changes were small, the response faded in at least one study, and some results reached significance in men but not in women. Reviews of the whole secretagogue class reach a similar place and call for longer, rigorous trials.⁶⁷⁴

Sermorelin’s human record goes back decades, and it splits cleanly in two. In children with idiopathic growth hormone deficiency, it was studied as a diagnostic test and as a daily treatment, reviewed in detail, and sold for years as a prescription medicine. That record is real, and it is old.

In adults, the sermorelin studies highlighted here are a handful of small ones from the 1990s; later, larger trials of GHRH analogs in older adults deserve their own reading. They agree on the hormones: GHRH(1-29) and its close analogs raise growth hormone in older people, and over a few weeks can bring IGF-1 up toward young-adult levels. They disagree, or simply run out of power, on what that means for the body. Strength, lean mass, skin and insulin sensitivity moved in some groups and not others.

What is missing from sermorelin’s record is the trial people actually want: a large, placebo-controlled study in adults, lasting a year or more, with outcomes such as muscle function, fat, bone and long-term safety. Reviews of the secretagogue class say rigorous long-term trials are few across the family, and findings from other secretagogues cannot settle sermorelin’s case. Until that trial exists, adult use rests on physiology and small studies. That justifies more controlled research, but it does not establish a favorable balance of benefit and risk for age-related use, and it is a weak basis for big promises.²³⁶⁷⁴

Sermorelin is the parent of a small family of GHRH-based peptides. CJC-1295 starts from the same 29 amino acids, swaps four of them to resist enzymes, and in its DAC form adds a group that binds albumin so it lasts about a week. Tesamorelin goes the other way, building on the full 44-amino-acid GHRH sequence.

The practical differences come down to duration and evidence. Sermorelin is short-acting and has the oldest record, mostly in children. CJC-1295 with DAC raises growth hormone for days but has only small trials in healthy adults. Tesamorelin has phase 3 trials and a current approval for a specific use in people with HIV.

All three need a working pituitary and stimulate the body’s own release, though keeping feedback in place does not guarantee that growth hormone or IGF-1 stays in a normal range. All three share the same metabolic watch points, since they end in more growth hormone and IGF-1.²⁸⁹¹⁰⁴

In the pediatric studies, both single intravenous doses and daily injections under the skin were well tolerated. Transient facial flushing and pain at the injection site were the most commonly reported adverse events.

The adult studies were small and short but broadly reassuring. The 1992 study found no change in fasting glucose, blood pressure or routine blood tests, the Hopkins study reported no significant adverse effects, and the only adverse effect in the 16-week analog study was a temporary rise in blood lipids that resolved by the end.

The open questions are the ones shared by every growth hormone secretagogue. Reviews of the class note some concern for higher blood glucose from lower insulin sensitivity, and they describe long-term safety, including cancer incidence, as insufficiently studied. Growth hormone and IGF-1 encourage cell growth, so a cancer history deserves a careful conversation.

People with a pituitary condition or prior pituitary surgery, diabetes or prediabetes, a pregnancy, or tested-sport obligations should talk to a clinician first. And with no approved product today, quality depends on ingredient sourcing, preparation, testing, storage and handling.²³⁶⁷⁴

Because growth hormone lowers insulin sensitivity, the labs most relevant to that concern are metabolic, and IGF-1, the direct readout of the pathway, is a specialist test a clinician can add. Fasting glucose gives the quick snapshot. HbA1c averages blood sugar over about three months, so it shows a slow drift that one morning reading would miss.

Fasting insulin adds context. Higher insulin with steady glucose can be consistent with the pancreas working harder to keep sugar in range, though it is not diagnostic on its own. None of this is a validated monitoring protocol for sermorelin; it is baseline context a clinician interprets. In the 16-week analog study, insulin sensitivity actually improved in men, which is a reminder that people differ and only measurement tells you which way you are going.

Vitals Vault starts peptide care with a blood panel. A licensed clinician reviews the results with your history and decides what fits, and a retest of the same markers shows how your body responded.⁷⁴

No sermorelin product is FDA-approved today. Geref’s applications were withdrawn in 2009, and in 2013 FDA determined that it was not withdrawn for reasons of safety or effectiveness. Sermorelin is not one of the six peptides covered by FDA’s October 2026 enforcement-discretion policy.

In sport, the World Anti-Doping Agency prohibits growth hormone releasing factors, including GHRH and its analogs, in and out of competition.¹¹²¹³

Sermorelin is the original GHRH drug: the shortest fully active piece of the body’s own growth hormone signal. It helped some growth hormone deficient children grow, served as a clean test of pituitary function, and, by FDA’s own finding, was not withdrawn for reasons of safety or effectiveness. In older adults, it reliably raises growth hormone, while the body changes in small trials were modest and uneven.

The most useful lesson comes from the 1992 study. In healthy older men, the pituitary could still answer when asked. That makes it worth asking, with a clinician, how sleep, visceral fat, insulin or something else may be shaping your own numbers, and whether changing those first would move them.²¹³